Molecular Templates Inc

NASDAQ:MTEMUnited States

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. The Company’s proprietary drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer. Its product pipeline includes MT-6402, MT-8421 and MT-0169. MT-6402 is an ETB consisting of a single chain variable fragments (scFv), with affinity for PD-L1, fused to the enzymatically active de-immunized SLTA and a HLA-A*02 class I antigen derived from the human cytomegalovirus (HCMV) pp65 protein. MT-8421, its ETB targeting CTLA-4, along with MT-6402. MT-0169 is designed to destroy CD38+ tumour cells through internalization of CD38 and cell destruction via a novel mechanism of action (enzymatic ribosomal destruction and immunogenic cell death).

Contact Information

Headquarters

9301 Amberglen Blvd Ste 100AUSTIN, TX, United States 78729-1153

Phone

512-896-1555

Fax

302-655-5049

Executives

Independent Chairman of the Board

Harold Selick

President, Chief Financial Officer, Treasurer

Jason Kim

Chief Executive Officer, Chief Scientific Officer, Director

Eric Poma

Interim Chief Medical Officer, Director

Gabriela Gruia

Independent Director

David Hoffmann